Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of a ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

"I'd say there's a 70% chance Mike Johnson is going to be speaker ... because that's just the way the swamp works," ...

Kentucky, wrote on X that a different speaker of the House of Representatives could win the vote if Louisiana Republican Mike ...

Speaker of the House Mike Johnson, R-La., speaks at a news conference with Rep. Chip Roy, R-Texas, left, House Majority ...

WASHINGTON — Rep. Mike Johnson, R-La., narrowly won reelection Friday as House speaker on a first ballot, overcoming ...

Speaker Mike Johnson (R-La.) on Thursday expressed confidence about his chances ahead of the House’s Speaker vote on Friday. ...

U.S. President-elect Donald Trump on Monday threw his support behind House Speaker Mike Johnson, who will stand for ...

House Republicans have said for weeks that Donald Trump would have the final say on whether Johnson keeps the gavel or is replaced.

A man in Maine is suing pharmeceutical giant Johnson & Johnson for $25 million over the death of his wife, claiming that use of its “dangerous and defective” talcum powder caused her death.